Short answer
Emergent BioSolutions Inc. (EBS) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $234M (up 66.3% year over year) with net income of −$180M.
Q2 2026 key financials · XBRL
- Revenue
- $234M
- +66.3% YoY · +50.1% QoQ
- Net income
- −$180M
- −1401.7% YoY · −2750.0% QoQ
- Operating margin
- -53.4%
- EPS (diluted)
- −$3.42
- −1610.0% YoY · −4985.7% QoQ
Source: XBRL data from the Emergent BioSolutions Inc. (EBS) Q2 2026 10-Q on SEC EDGAR. USD.
Emergent BioSolutions Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added restructuring risk triggered by August 5, 2026 plan involving workforce reductions and wet-laboratory closures
- Operational disruption risk from restructuring, including delivery issues and internal-control weaknesses during transition
- Regulatory compliance risk from third-party manufacturers potentially losing FDA authorization to manufacture products
- Competitive risk from Teva, Padagis, and Amneal generics eroding NARCAN® sales and pricing
- Financial risk from manufacturer price increases and supply interruptions pressuring margins, profitability, and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Emergent BioSolutions Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.